CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 120 enrolled
Drug / intervention
DFN-15 (Celecoxib Oral Solution) 62.5 mg +3 moredrug
Likely dose
DFN-15 (Celecoxib Oral Solution) 62.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03554772
NCT03554772Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, Safety and Pharmacokinetic Study of Single Doses of DFN-15 in Post-Surgical Dental Pain

Dr. Reddy's Laboratories Limited·interventional·Posted Jun 13, 2018·Updated Jan 22, 2021

In Brief

A Phase 2 clinical trial evaluating DFN-15 (Celecoxib Oral Solution) 62.5 mg, DFN-15 (Celecoxib Oral Solution) 125 mg, and 2 other interventions for Acute Pain. Completed, enrolled 120 participants across 1 site.

Detailed Summary

Efficacy, Tolerability, Safety and Pharmacokinetic Study of DFN-15 in Post-Surgical Dental Pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Pain
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJun 13, 2018
Enrollment StartJun 19, 2018
Primary CompletionAug 20, 2018
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.1 years ago

Interventions

DFN-15 (Celecoxib Oral Solution) 62.5 mgdrug

Oral Solution

DFN-15 (Celecoxib Oral Solution) 125 mgdrug

Oral Solution

DFN-15 (Celecoxib Oral Solution) 250 mgdrug

Oral Solution

Placebodrug

Oral Solution